About the Founder
Chris Morrison
Founder, ViaVerus · Creator of the Sell Now™ Method · 30+ Years in MedTech Commercialization
“Most companies launch a product and hope a market shows up. By then it’s too late — the market should be engineered before launch.”
Invite Chris to Speak30+
Years bringing disruptive medtech to market
450%
Growth led at Smith & Nephew
$2.6M
Pre-launch revenue engineered for Diagnostic Biochips — before ship date
10+
First-of-their-kind products taken to market
The Through-Line
The commercialization authority for pre-launch medtech.
Chris Morrison is the founder of ViaVerus and the creator of the Sell Now™ method, which helps medtech and deeptech founders engineer pre-launch revenue instead of waiting for a market to show up after launch.
Over more than 30 years bringing disruptive products to market, he led 450% growth at Smith & Nephew and has guided emerging companies from clinical promise to commercial proof — including a diagnostics company that generated $2.6M in revenue before its product shipped. His work focuses on the hardest, least-discussed part of building a medtech company: identifying who buys first, proving they’ll pay, and turning that into a repeatable commercial motion investors can underwrite.
On stage, Chris is known for a specific, contrarian point of view: markets form before launch, not after. He pushes founders and investors to treat first revenue as something engineered deliberately, not hoped for — and backs it with patterns drawn from decades of commercial leadership. Audiences leave with a concrete way to pressure-test their commercial assumptions and a sharper read on what real traction actually looks like.
Signature Talks
What Chris speaks about.
TALK 01
Sell Before You Ship: Engineering Pre-Launch Revenue in MedTech
Most teams treat commercialization as a post-clearance activity. Chris flips the sequence — showing how to identify first buyers, convert clinical interest into commitments, and book revenue before the product ships.
TALK 02
The Commercialization Gap: Why Cleared Devices Still Fail to Find Buyers
A clear-eyed look at why great technology stalls after launch, and the specific commercial moves that separate the companies that scale from the ones that quietly disappear.
TALK 03
Your First Ten Buyers: Building Commercial Proof Investors Will Underwrite
What real pre-launch traction looks like, how to generate it, and how to tell genuine demand apart from optimism — built for founders and the investors evaluating them.
Topics & Formats
Built for founder-and-investor audiences.
Topics & Themes
- Pre-launch go-to-market strategy for medtech, diagnostics, and deeptech
- Engineering first revenue and first buyers before launch
- Turning clinical interest into paying commitments
- What investors should underwrite as real commercial traction
- Building a repeatable commercial motion that compounds after launch
- Commercialization as a discipline, not a phase
Ideal Audiences & Formats
- MedTech, diagnostics, and deeptech founders 6–18 months from launch
- Commercial leaders who own the revenue number
- Investors and accelerators evaluating pre-launch traction
Formats: keynote, fireside chat, panelist, panel moderator, or workshop.
Why Audiences Book Chris
Credibility founders and investors respect.
Operator
30+ years bringing disruptive medtech products to market — and 450% growth led at Smith & Nephew.
Method
Creator of the Sell Now™ method for engineering pre-launch revenue in medtech and deeptech.
Results
Helped Diagnostic Biochips book $2.6M in pre-launch revenue — before the product shipped.
Endorsed
Trusted by commercial and clinical leaders at institutions including Duke and Johnson & Johnson.
Point of View
A specific, contrarian thesis — markets form before launch, not after — delivered without platitudes.
On Stage
Holds his own with founders and investors alike, and sends audiences home with something they can use Monday.
The Person Behind the Method
Part adventurer, part engineer.
Both sides show up in how Chris works. The adventurer is pulled toward selling the first-of-its-kind product no one has sold before — the uncertainty, the newness, doing something no one has done. The engineer wants to assemble the puzzle: find the repeatable sales motion as fast as possible, and bring order to the early chaos. Divergent and convergent, rational and creative — used together.
He earned a degree in Management Engineering from the University of Vermont, where he also played four years of intercollegiate soccer — an early lesson in being both an individual and part of a greater whole. His career started in healthcare, from managing ambulatory surgery centers to orthopedic implant sales, until a mid-90s startup selling early WiFi and handhelds into hospitals hooked him on disruptive technology for good. He never looked back.
Away from work, Chris is an avid skier and mountain biker who heads for the mountains every chance he gets, and a proud dad to his son, Evan.
The name says it: ‘via’ means path, ‘verus’ means true. ViaVerus — the true path.
“ViaVerus helped us meet the market where it actually was, not where we hoped it would be.”
— Brian Jamieson, CEO, Diagnostic Biochips